BACKGROUND: Sarcopenia is one of common problems among elderly worldwide. OBJECTIVE: To determine the prevalence of sarcopenia and related factors in community-dwelling elders Thai population. METHODS: This cross-sectional study was performed in 243 subjects aged over 60 years. All participants were evaluated for handgrip strength by dynamometer and for gait speed by walking a 6-m distance. The muscle mass for subjects who had abnormal grip strength and/or gait speed was evaluated by bioimpedance analysis (BIA). The prevalence of sarcopenia was calculated and factors related to sarcopenia were also analyzed. RESULTS: The mean age was 69.7 ± 6.9 years with three-fourths female participants. Approximate 60% of subjects were overweight. There were 74 participants (30.5%, (95% CI: 25.0%-36.5%)) with abnormal grip strength; gait speed and muscle mass. Males had more prevalence than females (33.9% vs. 29.3% respectively). There is higher prevalence with increasing age among both genders (17.9%, 41.4% and 80.0% in young old, middle old, and the very old groups respectively in male; and 11.5%, 49.1%, and 65.0% in female). After using multivariate analysis, age, body mass index (BMI), and quadriceps strengths were significantly related to sarcopenia with the adjusted odds ratio of 15.47 (95% CI: 4.93, 48.54), 12.84 (95% CI: 3.85, 42.82) and 3.77 (95% CI: 1.70, 8.37) respectively. CONCLUSIONS: Thirty percent of the community-based elderly experienced sarcopenia. As the prevalence is high, the screening for sarcopenia should be performed in community-dwelling elders especially older age, underweight subjects and lower quadriceps strength.
Aged ; Asian Continental Ancestry Group* ; Body Mass Index ; Cross-Sectional Studies ; Female ; Gait ; Hand Strength ; Humans ; Male ; Mass Screening ; Multivariate Analysis ; Odds Ratio ; Overweight ; Prevalence* ; Sarcopenia* ; Thinness ; Walking

Objectives: The Thai Osteoporosis Foundation (TOPF) is an academic organization that consists of a multidisciplinary group of healthcare professionals managing osteoporosis. The first clinical practice guideline for diagnosing and managing osteoporosis in Thailand was published by the TOPF in 2010, then updated in 2016 and 2021. This paper presents important updates of the guideline for the diagnosis and management of osteoporosis in Thailand. Methods: A panel of experts in the field of osteoporosis was recruited by the TOPF to review and update the TOPF position statement from 2016. Evidence was searched using the MEDLINE database through PubMed. Primary writers submitted their first drafts, which were reviewed, discussed, and integrated into the final document. Recommendations are based on reviews of the clinical evidence and experts' opinions. The recommendations are classified using the Grading of Recommendations, Assessment, Development, and Evaluation classification system. Results: The updated guideline comprises 90 recommendations divided into 12 main topics. This paper summarizes the recommendations focused on 4 main topics: the diagnosis and evaluation of osteoporosis, fracture risk assessment and indications for bone mineral density measurement, fracture risk categorization, management according to fracture risk, and pharmacological management of osteoporosis. Conclusions This updated clinical practice guideline is a practical tool to assist healthcare professionals in diagnosing, evaluating, and managing osteoporosis in Thailand.

Objectives: This study aimed to present the Asia-Pacific consensus on long-term and sequential therapy for osteoporosis, offering evidence-based recommendations for the effective management of this chronic condition.The primary focus is on achieving optimal fracture prevention through a comprehensive, individualized approach. Methods: A panel of experts convened to develop consensus statements by synthesizing the current literature and leveraging clinical expertise. The review encompassed long-term anti-osteoporosis medication goals, first-line treatments for individuals at very high fracture risk, and the strategic integration of anabolic and anti resorptive agents in sequential therapy approaches. Results: The panelists reached a consensus on 12 statements. Key recommendations included advocating for anabolic agents as the first-line treatment for individuals at very high fracture risk and transitioning to anti resorptive agents following the completion of anabolic therapy. Anabolic therapy remains an option for in dividuals experiencing new fractures or persistent high fracture risk despite antiresorptive treatment. In cases of inadequate response, the consensus recommended considering a switch to more potent medications. The consensus also addressed the management of medication-related complications, proposing alternatives instead of discontinuation of treatment. Conclusions This consensus provides a comprehensive, cost-effective strategy for fracture prevention with an emphasis on shared decision-making and the incorporation of country-specific case management systems, such as fracture liaison services. It serves as a valuable guide for healthcare professionals in the Asia-Pacific region, contributing to the ongoing evolution of osteoporosis management.